메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

HKSH Medical Group Signed Memorandum of Understanding with Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen To Advance Precision Proton Therapy, Furthering the Healthy China Initiative

HONG KONG, Dec. 24, 2025 -- In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH") and Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen ("Shenzhen Cancer Hospital") signed a memorandum of understanding ("MOU") on 11 December 2025. The MOU was signed by Dr. Walton LI, Chief Executive Officer of HKSH Medical Group and Medical Superintendent of Hong Kong Sanatorium & Hospital, and Professor WANG Luhua, Director of Shenzhen Cancer Hospital. The signing was
- 김갑성 기자
- 2025-12-24 15:49
Hakka Medicine Goes Global: Jiaying Pharmaceutical Launches the Global Promotion Plan for Hakka Medicine in Hong Kong

HONG KONG, Dec. 24, 2025 -- Recently, Guangdong Jiaying Pharmaceutical Co., Ltd. held the "First Hakka Medicine Historical and Cultural Symposium" and the "Jiaying Hakka Medicine - Double-ingredient Throat Wind Relief Powder Product Promotion Conference" in Hong Kong SAR. Centered on the theme of "Bringing Hakka Medicine to Global Hakka People," the conference brought together authoritative experts in traditional Chinese medicine from the Chinese mainland and Hong Kong SAR, renowned figures from cultural circles, and representatives of pharmaceutical enterprises.
- 김갑성 기자
- 2025-12-24 10:00
Nona Biosciences Expands Integrated Discovery-to-Clinical Capabilities Through Strategic Platform Growth

CAMBRIDGE, Mass., Dec. 24, 2025 -- Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the expansion of its integrated discovery and development framework to support early clinical development and Investigator-Initiated Trials (IITs). This expansion extends Nona's capabilities beyond discovery and IND-enabling activities to further strengthen CMC development, toxicology, and GMP manufacturing capabilities. Through strategic partnerships, platform acquisitions, and internal technology innovations,
- 김갑성 기자
- 2025-12-24 09:20
SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Gastric Cancer.

SEONGNAM, South Korea, Dec. 24, 2025 -- SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer nanoparticle drug under phase 1b/2 clinical trial for small cell lung cancer. SNB-101 is the world's first nanoparticle anticancer drug that has formulated extremely insoluble SN-38 into polymer nanoparticles, which is expected to significantly improve therapeutic efficacy and reduce side effects. It is currently undergoin
- 김갑성 기자
- 2025-12-24 07:37
Puainta Smashes Black Friday Records and Marks Successful Entry into UK Market

LOS ANGELES, Dec. 24, 2025 -- Puainta, a rapidly growing innovator in pet healthcare and wellness, today announced significant milestones following the 2025 Black Friday sales event. The brand reported an unprecedented surge in global sales, a successful strategic expansion into the UK market, and strengthened partnerships with leading animal rescue organizations, solidifying its position as a trusted leader in the pet care industry. Holiday Sales Surge Driven by Core Products During the 2025 Black Friday and Cyber Monday period, Puainta experienced record-bre
- 김갑성 기자
- 2025-12-24 00:00
NAVER D2SF-Backed Startups Participate in "CES 2026"

[ 메디채널 김갑성 기자 ] Five teams won CES Innovation Awards, including one Best of Innovation Award and three double Innovation Award winners Proving technological capabilities on the global stage across diverse sectors, including mobility, vertical AI, and healthcare Over 80% of portfolio companies targeting global markets, strengthening NAVER D2SF's role as a launchpad for Korean startups SEOUL, South Korea, Dec. 24, 2025 -- Eight startups backed by NAVER D2SF are participating in "CES 2026," the world's largest IT and consumer electronics exhibition. Most have already bee
- 김갑성 기자
- 2025-12-24 00:00
Bridging the "Last Mile" of Medical Innovation: ICMIS 2025 Successfully Concludes with Capital and Industry Collaborating to Accelerate Commercialization

HONG KONG, Dec. 23, 2025 -- In the current global MedTech landscape, technological breakthroughs are only the starting point. The real measure of scientific research is whether laboratory discoveries can be translated into safe, effective, and widely used clinical products. Yet the development of medical technology is often complex and challenging. In an increasingly rational market environment, constructing sustainable business models and aligning long-term capital with cutting-edge technologies have become critical priorities for innovation-driven enterprises. Within this context, th
- 김갑성 기자
- 2025-12-23 23:03
Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference

TAIPEI and SAN DIEGO, Dec. 23, 2025 -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued progress across its AI-enabled drug development platform at its 2025 annual investor conference, reinforcing its strategic position as the global immuno-oncology landscape enters a period of generational transition. Global blockbuster immune-oncology products now face major patent expirations before 2030 pharmaceutical companies
- 김갑성 기자
- 2025-12-23 20:00
Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy

DONGGUAN, China, Dec. 23, 2025 -- Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel fusion protein in Cell Reports Medicine. The peer-reviewed article details the preclinical and translational validation of FP008 (anti-PD-1 × IL-10M). This first-in-class bifunctional fusion protein is designed to address a fundamental limitation in cancer immunotherapy: the inability to reactivate terminally exhausted T cells within tumors. &
- 김갑성 기자
- 2025-12-23 13:03
HICC Pet × Marina One - Mental Wellness Month: Healing Moments with Dogs at HICC Pet Showroom

SINGAPORE, Dec. 23, 2025 -- This October, Marina One hosted a meaningful Mental Wellness Month event in the heart of Singapore's CBD. HICC Pet was pleased to participate as one of the contributing partners, offering pet-supported interactions to enhance the community wellness initiative. Marina One is a mixed-use development in Marina Bay, comprising Grade-A office towers, luxury residences, and a retail podium. One of its signature features is the Green Heart, a biodiverse garden courtyard designed as an urban sanctuary. As a hub for major corporate offices with a strong focus on sustainabil
- 김갑성 기자
- 2025-12-23 12:09

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 16시 00분